Website: https://SomaLogic.com
Dr. Peter Ganz is the Director of the Center of Excellence in Vascular Research at the Zuckerberg San Francisco General Hospital (ZSFG) and a Professor of Medicine at the University of California, San Francisco (UCSF). Dr. Ganz has been a pioneer in several areas of translational cardiovascular research.
Currently, Dr. Ganz, along with his collaborators at SomaLogic, is making important discoveries in the field of proteomics - using modified aptamers as binding reagents to quantify proteins in blood. He is using proteomics to construct prognostic models of disease (JAMA 2016;315:2532-2541) and to understand the biological pathways of diseases and biological mechanisms of drug therapies (Circulation. 2018;137:999–1010).
He co-led a study on using proteins as a single source of health care, known as the liquid health check (Nature Medicine 2019; 25: 1851–1857).
Dr. Ganz received his M.D. from Harvard, completed his residency at the Massachusetts General Hospital and cardiovascular fellowship at the Brigham and Women’s Hospital.
He spent 25 years directing cardiovascular research in the cardiac catheterization laboratories at the Brigham and Women’s Hospital and Harvard Medical School, prior to arriving at UCSF in 2008.
He likes to spend time with his wife, three children and one grandchild. His hobbies include hiking, biking, great food and passion for classical music.
Dr. Stephen Williams has been the Chief Medical Officer at SomaLogic since 2009. Prior to SomaLogic, Dr. Williams co-founded the pharma consultancy Decisionability, LLC in 2007 and authored the book Decisionability: The Skill to Make Your Decisions Productive, Practical and Painless.
From 1989-2007, Dr. Williams worked at Pfizer, Inc., initially in the Experimental Medicine group working in Exploratory Clinical Development and later as VP and Worldwide Head of Clinical Technology.
From 2003-2007, Dr. Williams was on the National Advisory Council for Biomedical imaging and Bioengineering at the National Institutes of Health. He helped to launch the Alzheimer’s Disease NeuroImaging (ADNI) study and helped form the FDA-FNIH-PhRMA biomarker consortium, serving on the inaugural executive committee.
Dr. Williams co-led the PhRMA position papers on “proof of concept,” surrogate endpoints and evidentiary standards for biomarkers and diagnostics.
Dr. Williams has degrees in physiology, medicine and surgery, and a Ph.D. in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College, London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.
He likes to spend time with his family (4 children and 3 grandchildren) and his hobbies include fitness training, skiing and mountain biking.
